Skip to main content

Table 1 Clinical and demographic characteristics

From: Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus

Characteristics N = 145
Male gender
 n (%) 129 (89.0)
Age, years
 Mean (SD) 37.8 (4.2)
Previous IVDU
 N (%) 129 (89.0)
Education
 University, n (%) 64 (44.1)
 Secondary, n (%) 79 (54.5)
 Primary, n (%) 2 (1.4)
Marital status
 Married, n (%) 85 (58.6)
 Widow/widower/divorce, n (%) 22 (15.2)
 Not married, n (%) 38 (26.2)
Employment status
 Regular employment, n (%) 67 (46.2)
 Non-regular employment, n (%) 56 (38.6)
 Not working, n (%) 22 (15.2)
Religion
 Moslem, n (%) 114 (78.6)
 Christian 29 (20.0)
 Buddhist 2 (1.4)
Alcohol use
 Active, n (%) 25 (17.2)
 Past, n (%) 111 (76.6)
 Never, n (%) 9 (6.2)
Tobacco use
 Active smoker, n (%) 73 (50.4)
 Past smoker, n (%) 66 (45.5)
 Never smoke, n (%) 6 (4.1)
BMI
 Mean (SD) 22.3 (3.5)
Hemoglobin, g/dL
 Mean (SD) 14.9 (4.3)
Recent CD4+ T cell count, cells/µL
 Median (IQR) 485 (392–675)
ART duration, years
 Median (IQR) 9 (4–12)
ART regimen
 NNRTI-based, n (%) 126 (86.9)
 PI-based, n (%) 19 (13.1)
HBV co-infection
 n (%) 6 (4.1)
HCV treatment history
 Treatment naïve, n (%) 132 (91)
 Interferon failure, n (%) 13 (9)
Fibrosis stage
 F0–F1, n (%) 86 (59.3)
 F2–F3, n (%) 30 (20.7)
 F4, n (%) 29 (20)
HCV-RNA, IU/mL
 > 800,000, n (%) 110 (75.9)
 < 800,000, n (%) 35 (24.1)
 Mean (SD), log10 6.22 (0.83)
HCV genotype
 1, n (%) 23 (15.8)
 2, n (%) 4 (2.8)
 3, n (%) 3 (2.1)
 4, n (%) 3 (2.1)
 Not available, n (%) 112 (77.2)
DAA combination
 SOF + DAC60, n (%) 30 (20.7)
 SOF + DAC90, n (%) 115 (79.3)
Duration of DAA treatment
 12 weeks, n (%) 116 (80)
 24 weeks, n (%) 29 (20)
DAA treatment response
 SVR12, n (%) 138 (95.5)
 Non-responder, n (%) 7 (4.5)